Compare Amylx Pharmaceuticals Inc (AMLX) vs Equinor ASA (EQNR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Equinor ASA — how do they compare? Amylx Pharmaceuticals Inc trades at $23.8 (market cap $2.64B), while Equinor ASA trades at $40.87 (market cap $97.58B). The key difference: Equinor ASA is far larger — about 37× Amylx Pharmaceuticals Inc's market cap, and Equinor ASA pays a 3.81% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | EQNR | |
|---|---|---|
Market Cap | $2.64B | $97.58B |
Sector | Health | Energy |
52-Week High | $24.19 | $42.40 |
52-Week Low | $7.82 | $22.41 |
Enterprise Value | $2.39B | $106.28B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
EQNR trades at $40.99, up 5.32% over 24 hours, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 revenue growth of 40% year-over-year despite an earnings miss, driven by higher energy prices and production. Recent news highlights a 22.2% monthly rally and ongoing share buybacks. Valuation ratios appear attractive with a P/E of 11.09 and EV/EBITDA of 2.3, while profitability metrics like a 21.32% ROE indicate efficient capital use.
The outlook for EQNR is positive, with opportunities from strategic investments in subsea projects and sustained cash flow generation supporting dividends and buybacks. Risks include volatility in oil and gas prices, execution challenges in growth projects, and potential regulatory shifts impacting energy markets. Analyst sentiment is mixed but leans cautious, with 56.53% holding a neutral stance amid valuation concerns after recent gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Equinor ASA
Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2021 (52% oil) and ended the year with 5.4 billion barrels of proven reserves (49% oil). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.
Read more on EQNR →
